Approximately 30% of women over the age of 70 fall per year. Vitamin D plays an important role in musculoskeletal health and is hypothesised to prevent falling. Two randomized controlled trials (RCTs) of high dose vitamin D identified increased falling rates in participants randomized to vitamin D (1,2). Given previous meta-analyses included studies of high dose vitamin D we revisited this topic focusing on RCTs that used a daily dose of at least 800IU with falls as their primary outcome. RCTs that used infrequent high doses with falls as the primary outcome were analysed separately for comparative purposes. We identified 9 studies of 2,633 subjects. Of these 7 studies (n=1,703 subjects) provided daily doses of vitamin D2 (n=2) or D3 (n=5) compared to either placebo or calcium. 43% of vitamin D supplemented subjects fell vs. 54% of control subjects with a pooled relative risk (RR) of 0.77 (0.66-0.90), P=0.001 for falls and low-moderate between study heterogeneity. Meta-regression identified type of vitamin D supplement as a potential source of heterogeneity. The pooled RR in the 2 studies using vitamin D2 was 0.89 (0.80-1.00), P=0.043 compared to the 5 studies using D3 (pooled RR of 0.67 [0.67-0.80], P<0.001 with no heterogeneity). Of the 2 RCTs (n=929) that gave infrequent vitamin (300,000IU D2 once or 150,000IU of D3 every 3 months) compared to placebo, 35% of vitamin D supplemented subjects fell vs. 33% of subjects given placebo. The pooled RR for falls in vitamin D supplemented subjects was 1.08 (0.91-1.28), P=0.392. These findings highlight the importance of daily dosing of vitamin D3 to prevent falls. Future trials should concentrate on daily doses of vitamin D3 and not induce toxic 25OHD serum levels by using large doses.